11647229001
Roche
Cell Proliferation ELISA, BrdU (colorimetric)
sufficient for ≤1,000 tests
Synonym(s):
cell proliferation
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
41116158
Recommended Products
usage
sufficient for ≤1,000 tests
Quality Level
manufacturer/tradename
Roche
technique(s)
ELISA: suitable
detection method
colorimetric
storage temp.
2-8°C
General description
Colorimetric immunoassay for the quantification of cell proliferation, based on the measurement of BrdU incorporation during DNA synthesis: a nonradioactive alternative to the [3H]-thymidine incorporation assay.
Specificity
The antibody conjugate reacts with the thymidine analogue 5-bromo-2′-deoxyuridine (BrdU) and with BrdU incorporated into DNA. For binding to BrdU incorporated into the DNA, the BrdU-labeled DNA has to be denatured. The antibody does not cross-react with any endogenous cellular components such as thymidine, uridine, or DNA.
Application
For research use only. Not for use in diagnostic procedures.
The Cell Proliferation ELISA, BrdU (colorimetric) belongs to the second, improved generation of kits for measuring DNA synthesis. It is a precise, fast, and simple colorimetric alternative to quantitate cell proliferation based on the measurement of BrdU incorporation during DNA synthesis in replicating (cycling) cells. Thus, the Cell Proliferation ELISA can be used in many different in vitro cell systems. For example:
The Cell Proliferation ELISA, BrdU (colorimetric) belongs to the second, improved generation of kits for measuring DNA synthesis. It is a precise, fast, and simple colorimetric alternative to quantitate cell proliferation based on the measurement of BrdU incorporation during DNA synthesis in replicating (cycling) cells. Thus, the Cell Proliferation ELISA can be used in many different in vitro cell systems. For example:
- Detection and quantification of cell proliferation induced by growth factors and cytokines
- Determination of the inhibitory or stimulatory effects of various compounds on cell proliferation in environmental and biomedical research, and in the food, cosmetic, and pharmaceutical industries
- Measurement of the immunoreactivity of lymphocytes, stimulated by mitogens or antigens
- Analysis of the chemosensitivity of tumor cells to different cytostatic drugs in medical research
- Testing of biocompatibility of various scaffolds, employed in bone tissue engineering, for bone cell growth
Packaging
1 kit containing 6 components.
Preparation Note
Working concentration: The kit antibody (Anti-BrdU-peroxidase) has, after reconstitution, a concentration of 7.5 U/ml, after dilution 0.075 U/ml. Instead of the kit antibody, you can also use the Anti-BrdU-Antibody, Fab fragments.This antibody is double-concentrated, so you have to dilute it after reconstitution in 1 ml with 1:200.
Working solution: BrdU labeling solution
Dilute BrdU labeling reagent 1:100 with sterile culture medium (resulting concentration: 100 μM BrdU).
For one 96-well MP, 1 ml BrdU labeling solution is required if the cells were cultured in 100 μl /well (10 μl/well) and 2 ml BrdU labeling solution is required if the cells were cultured in 200 μl/well (20 μl/well).
Anti-BrdU-peroxidase stock solution
Dissolve Anti-BrdU-peroxidase in 1.1 ml double-dist. water for 10 minutes and mix thoroughly.
Anti-BrdU-peroxidase working solution
Dilute Anti-BrdU-peroxidase stock solution 1:100 with antibody dilution solution. For one 96-well MP dilute 100 μl Anti-BrdU-peroxidase stock solution in 10 ml antibody dilution solution
Washing solution
Dilute Washing buffer concentrate 1:10 with double-dist. water.
For one 96-well MP dilute 10 ml Washing buffer concentrate with 90 ml double-dist. water.
Storage conditions (working solution): BrdU labeling solution
The undiluted BrdU labeling reagent (1000x): At 2 to 8 °C for several months protected from light.
The diluted BrdU labeling reagent: At 2 to 8 °C stable for several weeks. Store protected from light. For long-term storage it is recommended to store the BrdU labeling solution in aliquots at -15 to -25 °C.
Anti-BrdU-peroxidase stock solution
At 2 to 8 °C for several months. For long-term storage it is recommended to store the solution in aliquots at -15 to -25 °C.
Anti-BrdU-peroxidase working solution
Prepare shortly before use. Do not store.
Washing solution
At 2 to 8 °C for several weeks.
Working solution: BrdU labeling solution
Dilute BrdU labeling reagent 1:100 with sterile culture medium (resulting concentration: 100 μM BrdU).
For one 96-well MP, 1 ml BrdU labeling solution is required if the cells were cultured in 100 μl /well (10 μl/well) and 2 ml BrdU labeling solution is required if the cells were cultured in 200 μl/well (20 μl/well).
Anti-BrdU-peroxidase stock solution
Dissolve Anti-BrdU-peroxidase in 1.1 ml double-dist. water for 10 minutes and mix thoroughly.
Anti-BrdU-peroxidase working solution
Dilute Anti-BrdU-peroxidase stock solution 1:100 with antibody dilution solution. For one 96-well MP dilute 100 μl Anti-BrdU-peroxidase stock solution in 10 ml antibody dilution solution
Washing solution
Dilute Washing buffer concentrate 1:10 with double-dist. water.
For one 96-well MP dilute 10 ml Washing buffer concentrate with 90 ml double-dist. water.
Storage conditions (working solution): BrdU labeling solution
The undiluted BrdU labeling reagent (1000x): At 2 to 8 °C for several months protected from light.
The diluted BrdU labeling reagent: At 2 to 8 °C stable for several weeks. Store protected from light. For long-term storage it is recommended to store the BrdU labeling solution in aliquots at -15 to -25 °C.
Anti-BrdU-peroxidase stock solution
At 2 to 8 °C for several months. For long-term storage it is recommended to store the solution in aliquots at -15 to -25 °C.
Anti-BrdU-peroxidase working solution
Prepare shortly before use. Do not store.
Washing solution
At 2 to 8 °C for several weeks.
Reconstitution
The working solution for the antibody should be phosphate buffered saline containing 1% BSA, pH 7.4
Other Notes
For life science research only. Not for use in diagnostic procedures.
Kit Components Only
Product No.
Description
- BrdU Labeling Reagent
- FixDenat ready-to-use
- Anti-BrdU-peroxidase antibody
- Antibody Dilution Solution ready-to-use
- Washing Buffer PBS 10x concentrated
- Substrate Solution TMB ready-to-use
Signal Word
Danger
Hazard Statements
Precautionary Statements
Hazard Classifications
Eye Irrit. 2 - Flam. Liq. 2 - Muta. 1B - Skin Sens. 1
Storage Class Code
3 - Flammable liquids
WGK
WGK 1
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Lutz Wollin et al.
The Journal of pharmacology and experimental therapeutics, 349(2), 209-220 (2014-02-22)
The tyrosine kinase inhibitor nintedanib (BIBF 1120) is in clinical development for the treatment of idiopathic pulmonary fibrosis. To explore its mode of action, nintedanib was tested in human lung fibroblasts and mouse models of lung fibrosis. Human lung fibroblasts
Yanqing Gong et al.
Oncotarget, 6(28), 25856-25867 (2015-08-28)
The coiled coil is a superhelical structural protein motif involved in a diverse array of biological functions, and the abnormal expression of the coiled-coil domain containing proteins has a direct link with the phenotype of tumor cell migration, invasion and
Jia-Ang Shi et al.
International journal of molecular medicine, 34(1), 237-243 (2014-04-24)
It is known that microRNA-219 (miR-219) expression is downregulated in medulloblastoma. In the present study, we investigated the expression, targets and functional effects of miR-219 in D283-MED medulloblastoma cells. We first demonstrated that miR-219 not only inhibits proliferation, but also
Yoshinobu Takahashi et al.
Oncology letters, 14(1), 264-270 (2017-07-12)
Whether the poor prognosis of primary central nervous system lymphoma (PCNSL) compared with systemic diffuse large B cell lymphoma (DLBCL) is attributable to the immune privilege of the intracerebral location or to intrinsic differences in the biological characteristics of two
R B Erlich et al.
British journal of cancer, 106(1), 107-115 (2011-11-26)
We examine the potential value of a series of clinically relevant PI3K-mTOR inhibitors alone, or in combination with histone deacetylase inhibitors, in a model of head and neck squamous cell carcinoma (HNSCC). Head and neck squamous cell carcinoma cell lines
Articles
Regulation of the cell cycle involves processes crucial to the survival of a cell, including the detection and repair of genetic damage as well as the prevention of uncontrolled cell division associated with cancer. The cell cycle is a four-stage process in which the cell 1) increases in size (G1-stage), 2) copies its DNA (synthesis, S-stage), 3) prepares to divide (G2-stage), and 4) divides (mitosis, M-stage). Due to their anionic nature, nucleoside triphosphates (NTPs), the building blocks of both RNA and DNA, do not permeate cell membranes.
Cell based assays for cell proliferation (BrdU, MTT, WST1), cell viability and cytotoxicity experiments for applications in cancer, neuroscience and stem cell research.
Protocols
Cell Proliferation ELISA, BrdU (colorimetric) Protocol & Troubleshooting
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service